Madrigal to grapple with lack of awareness about NASH ahead of potential FDA approval

Madri­gal Phar­ma­ceu­ti­cals may be first in line to bring a NASH drug to mar­ket, but the com­pa­ny is al­so tasked with teach­ing Amer­i­cans and their doc­tors about the lit­tle-known liv­er dis­ease.

The FDA is set to de­cide whether to ap­prove Madri­gal’s resme­tirom this week. An ap­proval would rep­re­sent a long-await­ed suc­cess in a field where the cur­rent stan­dard of care is di­et and ex­er­cise — and a big mar­ket op­por­tu­ni­ty for Madri­gal. An es­ti­mat­ed 5% of Amer­i­cans have NASH, which is al­so known as meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH). Jef­feries an­a­lysts said in Sep­tem­ber that resme­tirom could reach $3 bil­lion in peak sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.